TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00905658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: therapeutic nutritional supplementation
Description: Patients receive systematic nutritional supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: therapeutic nutritional supplementation
Description: Patients receive systematic nutritional supplementation

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: standard follow-up care
Description: Patients undergo standard monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Patients undergo standard monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Patients undergo standard monitoring
Study: NCT02635750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Study: NCT02621385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: substrate for drug-drug interaction assessment
Study: NCT04024696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Abexinostat Tosylate Tablets
Study: NCT04562324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
Description: Medications to relieve anxiety

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
Description: Medications to relieve anxiety

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback system
Description: EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback system
Description: EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
Study: NCT02635750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study: NCT01654822

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical swab with Cervex-Brush-Combi at T1
Study: NCT01914978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food allergy handbook for parents
Description: The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food allergy treatment as usual
Study: NCT01364727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 35 mg/m2; IV on days 1-3 each 3 week cycle
Study: NCT03681483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5126766
Description: RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
Study: NCT04562324

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback system
Description: EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback system
Description: EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
Study: NCT01079715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
Study: NCT01532453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-3511356
Description: Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sun Protection Measures
Description: Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
Study: NCT00117767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine hydrochloride (HCl)
Description: Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Griseofulvin
Description: Griseofulvin pediatric suspension o.d. administration
Study: NCT03661385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Addition of nitric oxide 20ppm into bypass circuit
Study: NCT04006769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate tablet
Study: NCT04507074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction therapy
Description: The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lumbar traction therapy
Description: The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
Study: NCT01923064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lauromacrogol
Description: endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
Study: NCT04230538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO Walker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional plaster cast
Study: NCT01693003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 150 µg d.o. during the first 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: 150 µg d.o. during the first 3 weeks
Study: NCT03910699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-row circular stapler
Description: Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two-row circular stapler
Description: Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
Study: NCT01855555

Intervention type: DRUG
Intervention: sedation with propofol
Description: When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported.
Study: NCT02132338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Education Health Program
Description: The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
Study: NCT00848991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Precedex
Description: Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: evaulation of propofol for emergence from anesthesia
Study: NCT01693003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 150 µg d.o. during 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 150 µg d.o. during 3 weeks
Study: NCT03940092

Intervention type: OTHER
Intervention: MRI
Description: This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery.

Intervention type: OTHER
Intervention: MRI
Description: This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery.

Intervention type: OTHER
Intervention: PET/MRI
Description: Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
Study: NCT00947466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Transdermal patch
Study: NCT02635750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study: NCT04377087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Study: NCT03594344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
Study: NCT01196611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Amplification
Description: Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function Voice Exercises
Description: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
Study: NCT02092103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Milking
Description: See description in cord milking arm.
Study: NCT00731198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Description: Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine-N-butylbromide
Description: Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
Study: NCT02184117

Intervention type: DRUG
Intervention: Adenosine
Description: Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
Study: NCT02578368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks
Study: NCT02184117

Intervention type: DRUG
Intervention: Contrast Media
Description: Intracoronary injection of contrast medium to induce hyperemia for contrast FFR

Intervention type: DRUG
Intervention: Resting conditions
Description: Baseline measurement of aortic and coronary pressures
Study: NCT03880890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenoidotomy versus sphenoid nasalisation
Description: sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenoidotomy versus sphenoid nasalisation
Description: sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
Study: NCT03387046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-aspartate
Description: D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
Study: NCT03387046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN beta-1a
Description: IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFN beta-1a
Description: IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Study: NCT03387046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
Study: NCT03387046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Study: NCT01509924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activation on Prescription
Description: The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
Study: NCT03791021

Intervention type: DIAGNOSTIC_TEST
Intervention: draw a person (DAP)
Description: the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Description: measure of postpartum depression symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory- II (BDI-II)
Description: BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/200 FDC tablets
Study: NCT03392233

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/200 FDC tablets
Study: NCT03047005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB medication (Naltrexone Bupropion combination)
Description: NB medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02581553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 200 mg
Study: NCT00944294

Intervention type: DRUG
Group type: OTHER
Intervention: binodenoson
Description: 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

Intervention type: DRUG
Group type: OTHER
Intervention: binodenoson
Description: 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study: NCT03791021

Intervention type: DIAGNOSTIC_TEST
Intervention: Traumatic Events Questionnaire (TEQ)
Description: The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
Study: NCT00944294

Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study: NCT04582019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent extraction
Description: stent extraction using magnetic retriever or flexible cystoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent extraction
Description: stent extraction using magnetic retriever or flexible cystoscope